Literature DB >> 24442368

Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.

Angus Dalgleish1, Peter Featherstone, Viatcheslav Vlassov, Moshe Rogosnitzky.   

Abstract

A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24442368     DOI： 10.1007/s10637-014-0063-z

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  28 in total

1.  Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer.

Authors:  F Andre; N Cabioglu; H Assi; J C Sabourin; S Delaloge; A Sahin; K Broglio; J P Spano; C Combadiere; C Bucana; J C Soria; M Cristofanilli
Journal:  Ann Oncol       Date:  2006-04-20       Impact factor: 32.976

2.  Carcinoma of the prostate mimicking lymphoma.

Authors:  S M Phillips; D R Ferry; S J Lee
Journal:  Br J Urol       Date:  1994-05

Review 3.  Homeostatic chemokine receptors and organ-specific metastasis.

Authors:  Albert Zlotnik; Amanda M Burkhardt; Bernhard Homey
Journal:  Nat Rev Immunol       Date:  2011-08-25       Impact factor: 53.106

4.  Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.

Authors:  Manuel Alfonso-Pérez; Sonia López-Giral; Nuria E Quintana; Javier Loscertales; Patricia Martín-Jiménez; Cecilia Muñoz
Journal:  J Leukoc Biol       Date:  2006-04-07       Impact factor: 4.962

5.  A case of prostate cancer in 34 year old man presenting with generalized lymphadenopathy mimicking malignant lymphoma.

Authors:  M J Ahn; S J Oh; Y Y Lee; T J Jung; I S Kim; I Y Choi; S J Jang; Y W Park; K Y Shin; Y S Kim
Journal:  J Korean Med Sci       Date:  1997-06       Impact factor: 2.153

6.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

7.  Prostate cancer mimicking malignant lymphoma.

Authors:  M W Oster; M Wolff; S Starrett
Journal:  Med Pediatr Oncol       Date:  1979

8.  Metastatic carcinoma of the prostate presenting radiographically as lymphoma.

Authors:  B S Stein; F J Shea
Journal:  J Urol       Date:  1983-08       Impact factor: 7.450

9.  CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia.

Authors:  Silvia Buonamici; Thomas Trimarchi; Maria Grazia Ruocco; Linsey Reavie; Severine Cathelin; Brenton G Mar; Apostolos Klinakis; Yevgeniy Lukyanov; Jen-Chieh Tseng; Filiz Sen; Eric Gehrie; Mengling Li; Elizabeth Newcomb; Jiri Zavadil; Daniel Meruelo; Martin Lipp; Sherif Ibrahim; Argiris Efstratiadis; David Zagzag; Jonathan S Bromberg; Michael L Dustin; Iannis Aifantis
Journal:  Nature       Date:  2009-06-18       Impact factor: 49.962

10.  Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.

Authors:  Sonia López-Giral; Nuria E Quintana; María Cabrerizo; Manuel Alfonso-Pérez; Mónica Sala-Valdés; Valle Gómez Garcia De Soria; José María Fernández-Rañada; Elena Fernández-Ruiz; Cecilia Muñoz
Journal:  J Leukoc Biol       Date:  2004-05-20       Impact factor: 4.962
View more
  8 in total

Review 1.  A primer on tumour immunology and prostate cancer immunotherapy.

Authors:  Runhan Ren; Madhuri Koti; Thomas Hamilton; Charles H Graham; Jasmir G Nayak; Jas Singh; Darrel E Drachenberg; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

Review 2.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

Review 3.  Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach.

Authors:  Božo Krušlin; Davor Tomas; Tihana Džombeta; Marija Milković-Periša; Monika Ulamec
Journal:  Front Oncol       Date:  2017-04-25       Impact factor: 6.244

4.  Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.

Authors:  Jonathan F Anker; Anum F Naseem; Hanlin Mok; Anthony J Schaeffer; Sarki A Abdulkadir; Praveen Thumbikat
Journal:  Nat Commun       Date:  2018-04-23       Impact factor: 14.919

5.  Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer.

Authors:  Frank Waldbillig; Katja Nitschke; Abdallah Abdelhadi; Jost von Hardenberg; Philipp Nuhn; Malin Nientiedt; Cleo-Aron Weis; Maurice Stephan Michel; Philipp Erben; Thomas Stefan Worst
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

Review 6.  Immune Infiltration and Prostate Cancer.

Authors:  Amy Strasner; Michael Karin
Journal:  Front Oncol       Date:  2015-07-08       Impact factor: 6.244

7.  The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

Authors:  Monique H M Melis; Ekaterina Nevedomskaya; Johan van Burgsteden; Bianca Cioni; Hester J T van Zeeburg; Ji-Ying Song; John Zevenhoven; Lukas J A C Hawinkels; Karin E de Visser; Andries M Bergman
Journal:  Oncotarget       Date:  2017-09-28

8.  Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.

Authors:  Stephen T Ryan; Jing Zhang; Danielle N Burner; Michael Liss; Emily Pittman; Michelle Muldong; Ahmed Shabaik; Jason Woo; Nicole Basler; Jonathan Cunha; Shabnam Shalapour; Monica V Estrada; Michael Karin; Karen Messer; Stephen Howell; Christopher J Kane; Christina A M Jamieson
Journal:  J Transl Med       Date:  2020-05-28       Impact factor: 8.440
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.